Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus, CKD and Albuminuria

Interventions: Drug: Dapagliflozin 10 mg
Drug: Saxagliptin 2.5 mg
Drug: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg

First Posted Date: 2015-09-14

Last Posted Date: 2019-08-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 459

Registration Number: NCT02547935

Locations: 🇨🇳
Research Site, Yong-Kang City, Taiwan

Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis

Phase 2

Completed

Conditions: Lupus Nephritis

Interventions: Biological: Anifrolumab
Drug: Placebo

First Posted Date: 2015-09-14

Last Posted Date: 2021-11-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 147

Registration Number: NCT02547922

Locations: 🇬🇧
Research Site, London, United Kingdom

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

Phase 1

Active, not recruiting

Conditions: Muscle Invasive Bladder Cancer

Interventions: Drug: AZD4547
Drug: MEDI4736
Drug: Vistusertib
Drug: AZD9150
Drug: Olaparib
Drug: AZD1775
Drug: Selumetinib

First Posted Date: 2015-09-11

Last Posted Date: 2025-04-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 117

Registration Number: NCT02546661

Locations: 🇬🇧
Research Site, Southampton, United Kingdom

A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis

Phase 3

Completed

Conditions: Atherosclerosis

Interventions: Drug: Placebo
Drug: Rosuvastatin

First Posted Date: 2015-09-10

Last Posted Date: 2019-12-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 543

Registration Number: NCT02546323

Locations: 🇨🇳
Research Site, Xian, China

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

Phase 3

Active, not recruiting

Conditions: Non Small Cell Lung Carcinoma NSCLC

Interventions: Biological: Durvalumab +Tremelimumab
Drug: Paclitaxel + carboplatin
Drug: Gemcitabine + cisplatin
Drug: Gemcitabine + carboplatin
Drug: Pemetrexed + cisplatin
Drug: Pemetrexed + carboplatin

First Posted Date: 2015-09-07

Last Posted Date: 2025-06-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 953

Registration Number: NCT02542293

Locations: 🇬🇧
Research Site, Wolverhampton, United Kingdom

SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

First Posted Date: 2015-09-07

Last Posted Date: 2017-11-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 412

Registration Number: NCT02543476

Locations: 🇪🇸
Research Site, Sevilla, Spain

A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lanabecestat
Drug: Warfarin

First Posted Date: 2015-09-04

Last Posted Date: 2019-11-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 15

Registration Number: NCT02540668

Locations: 🇺🇸
Covance Clinical Research Inc, Evansville, Indiana, United States

A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Biological: Bydureon

First Posted Date: 2015-08-26

Last Posted Date: 2019-05-31

Lead Sponsor: AstraZeneca

Target Recruit Count: 110

Registration Number: NCT02533453

Locations: 🇰🇷
Research Site, Wonju-si, Korea, Republic of

A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects

Phase 1

Completed

Conditions: Pharmacodynamics
Healthy Subjects

Interventions: Drug: AZD9977 oral suspension
Drug: AZD9977 placebo oral suspension
Drug: Fludrocortisone, tablets
Drug: Eplerenone, tablets

First Posted Date: 2015-08-26

Last Posted Date: 2017-03-29

Lead Sponsor: AstraZeneca

Target Recruit Count: 40

Registration Number: NCT02532998

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

Phase IV O2 Consumption Study in COPD Patients.

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol
Drug: Matching Placebo pMDI 160/4.5 μg

First Posted Date: 2015-08-26

Last Posted Date: 2018-07-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 51

Registration Number: NCT02533505

Locations: 🇺🇸
Research Site, Spartanburg, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy